Krempa David's Form 4 filing
Eton Pharmaceuticals, Inc. (ETON) · filed Jun 16, 2025
- Accession no.
- 0001437749-25-020518
- Filed
- Jun 16, 2025
- Trade date
- Jun 12-16, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $504.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Krempa DavidCIK 0001968254 | Officer (Chief Business Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 12, 2025 | Common Stock | SSaleDisposed | −16,977 | $14.92 | −$253,296.84 | 629,669 | Direct | |
| Jun 13, 2025 | Common Stock | SSaleDisposed | −6,800 | $14.77 | −$100,436 | 622,869 | Direct | |
| Jun 16, 2025 | Common Stock | SSaleDisposed | −10,223 | $14.73 | −$150,584.79 | 612,646 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.